AKAMAI TECHNOLOGIES INC (NASDAQ: AKAM) stock suffered a major decline of -21.7% on 2/21/25. The shares closed at $76.73. Moreover, exceptionally high trading volume at 991% of normal accompanied the decline. The stock has performed […]
Stock Rating Upgrade In recent days the Value Trend Rating for Virtra Inc (NASDAQ: VTSI) improved from D to C reflecting improving fundamentals and high Appreciation Potential. Recent Price Action Virtra Inc (NASDAQ: VTSI) stock […]
Stock Rating Downgrade The Value Trend Rating for TELUS Corp (NYSE: TU) weakened recently from B to C reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next […]
TAL Education Group (NYSE: TAL) has recently enjoyed important positive changes in fundamentals: the consensus estimate for February, 2024 increased significantly, the stock’s power rating rose above 70, and the consensus estimate for February, 2025 […]
Stock Rating Upgrade The Value Trend Rating for Stryker Corp (NYSE: SYK) improved in the last week from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included […]
Stock Rating Downgrade Reflecting eroding fundamentals and low Appreciation Potential, the Value Trend Rating for Rand Capital Corp (NASDAQ: RAND) weakened in the last week. RAND’s current Value Trend Rating is C and the prior […]
Stock Rating Upgrade Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for NewMarket Corp (NYSE: NEU) improved during the last several trading days. NEU’s current Value Trend Rating is C and the […]
Stock Rating Upgrade In the last week the Value Trend Rating for Neogenomics Inc (NASDAQ: NEO) improved from D to C reflecting improving fundamentals and high Appreciation Potential. Recent Price Action Neogenomics Inc (NASDAQ: NEO) […]
For its fourth fiscal quarter (ending December 31), National Presto Industries Inc. (NYSE: NPK) has reported a 57% increase in E.P.S. from $1.85 a year ago to $2.91 in the current quarter. For the latest […]
For its fourth fiscal quarter (ending December 31), Travere Therapeutics Inc (NASDAQ: TVTX) has reported a -37% decline in E.P.S. from $-1.16 a year ago to $-0.73 in the current quarter. E.P.S. were $-4.06 for […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research